Hegseth’s dubious low-T screening may flag up to 25 percent of the Army

Up to a quarter of the Army may face unnecessary medical evaluations and potential overtreatment from a new mandatory low-T screening.

A new study published in JAMA estimates that up to 25 percent of active-duty Army members could receive a low testosterone screening result from a mandatory military-wide screening program. The screening, announced by Defense Secretary Pete Hegseth in July and with clinical guidance released in September, is raising concerns among medical experts. Organizations like the Endocrine Society and the American Urological Association recommend against such blanket screenings due to the high variability of testosterone levels and the low prevalence of actual medical conditions. Researchers analyzed data from 479 male, active-duty Army service members, finding that using the Pentagon's threshold of less than 300 ng/dL, approximately 26 percent of service members would screen as low. If a lower CDC threshold of 264 ng/dL is used, about 15 percent would screen low. These results are significantly higher than the estimated 1 percent prevalence of actual male hypogonadism, suggesting a high rate of false positives that could lead to unnecessary evaluations, inaccurate diagnoses, and potential overtreatment.

The mandatory low-T screening for Army members deviates from standard medical practice, which typically requires symptomatic presentation before testing. This approach risks overwhelming the healthcare system with evaluations for individuals who do not have clinically significant hypogonadism, a condition affecting at most 1 percent of men. The study highlights that factors like obesity, stress, and poor sleep can temporarily lower testosterone levels, leading to false positives in a single screening. This broad screening strategy could lead to widespread unnecessary follow-up tests, counseling, and potentially long-term treatments with adverse effects, including infertility.

This widespread screening initiative signals a potential shift in military healthcare priorities, focusing on broad population-level screening rather than symptom-driven diagnostics. The high estimated rate of false positives could strain medical resources and lead to an increase in diagnosed 'low testosterone' cases, which may not reflect underlying health issues. Future attention should focus on the actual implementation of follow-up procedures and the long-term health outcomes for service members subjected to this screening, as well as whether similar broad screenings might be considered for other health metrics within the military.